The importance of dose and schedule in cancer chemotherapy: Haematological cancer

Research output: Contribution to journalReview articlepeer-review

3 Scopus citations

Abstract

Haematological cancers have been the prototype malignant diseases in which dose-intensive strategies have been tested. To date, dose intensification within the conventional dose range has not been shown to result in improved long-term survival in prospective studies. The use of haemopoietic growth factors is important in maintaining adequate doses of chemotherapy, and reducing life-threatening complications, but growth-factor supported dose intensification has yet to be shown to improve outcome in randomised clinical trials. Dose escalation with high-dose therapy and stem cell support has produced encouraging results in several haematological malignancies, Preliminary evidence is also suggesting that it may Improve long-term disease-free survival for some patients, but the results of ongoing clinical trials are needed to confirm these encouraging early results.

Original languageEnglish (US)
Pages (from-to)7-15
Number of pages9
JournalAnti-Cancer Drugs
Volume6
Issue numberSUPPL. 5
DOIs
StatePublished - Jan 1 1995
Externally publishedYes

ASJC Scopus subject areas

  • Oncology
  • Pharmacology
  • Pharmacology (medical)
  • Cancer Research

Fingerprint Dive into the research topics of 'The importance of dose and schedule in cancer chemotherapy: Haematological cancer'. Together they form a unique fingerprint.

Cite this